Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
Greenwich LifeSciences announced it cannot file its Form 10-K for fiscal year 2025 on time due to delays in auditor coordination and significant accounts payable adjustments. The company attributes the delay to the need for dual auditor agreement on large increases in accounts payable related to its Phase III clinical trial enrollment in Europe. Management claims the adjustments are not material to fundamentals, citing an unaudited cash balance of $10.5 million as of March 31, 2026.
Key figures
- Cash balance
- 10500000
- Patients screened
- 1300
- Screen rate per year
- 800
- Dth reaction increase
- 290%
- Net cash used operating
- 9900000
- Recurrence reduction preliminary
- 70-80%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.